Vimarsana
Biggest News Aggregation in the World

Inflamm Regen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Inflamm Regen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Inflamm Regen Today - Breaking & Trending Today

WuXi Biologics and Toregem BioPharma Sign MOU for Development of Anti-USAG-1 Antibody - Vimarsana News

WuXi Biologics and Toregem BioPharma Sign MOU for Development of Anti-USAG-1 Antibody

SHANGHAI, Oct. 11, 2022 /PRNewswire/ -- WuXi Biologics and Toregem BioPharma Sign MOU for Development of Anti-USAG-1 Antibody

WuXi Biologics and Toregem BioPharma Sign MOU for Development of Anti-USAG-1 Antibody - Vimarsana News

WuXi Biologics and Toregem BioPharma Sign MOU for Development of Anti-USAG-1 Antibody

/PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), and Toregem...

Aptorum Group Limited: Aptorum Group Enters Into Material Transfer and Exclusive Option-To-License Agreement with Yale University for Its Novel Immunomodulators Potentially Targeting Autoimmune and Oncology Diseases - Vimarsana News

Aptorum Group Limited: Aptorum Group Enters Into Material Transfer and Exclusive Option-To-License Agreement with Yale University for Its Novel Immunomodulators Potentially Targeting Autoimmune and Oncology Diseases

(0) Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ("Aptorum Group" or "Aptorum"), a clinical-stage biopharmaceutical company, through its affiliate, has entered into a material transfer and option agreement ("Agreement") with Yale University ("Yale") to evaluate a group of preclinical stage novel immunomodulators. The novel immunomodulators may potentially target autoimmune and oncology diseases, including but not limited to, rheumatoid arthritis, lupus and sclerosis, as well as a variety of cancers, all subject to further preclinical development and testing. Aptor...